(Reuters) - Drugmaker Vectura Group Plc (L:VEC) said it raised its revenue expectations for the nine months to Dec. 31 following strong trading to the end of August.
The company, which agreed to buy rival SkyePharma in March for 441 million pounds, said revenue from oral, inhaled, and non-inhaled products was ahead of its expectations.